Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated June 23, 2025, reports a significant regulatory milestone for its investigational drug, linerixibat. The announcement concerns the acceptance of the marketing authorisation application (MAA) by the European Medicines Agency (EMA) for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific regulatory event rather than a financial results announcement.
Material Changes and Developments
- Regulatory Acceptance: The EMA has accepted the MAA for linerixibat, following an earlier acceptance by the US FDA earlier in June 2025.
- Clinical Data: The application is based on positive results from the GLISTEN Phase III trial, which met both primary and key secondary endpoints.
- Trial Outcomes: The study demonstrated rapid, significant, and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo in 238 patients across 19 countries.
- Safety Profile: The safety profile of linerixibat was consistent with previous studies and the mechanism of IBAT inhibition.
Guidance, Outlook, and Risks
Management Commentary: Kaivan Khavandi, SVP of Global Head, Respiratory, Immunology & Inflammation R&D, stated that the EMA acceptance marks a significant step forward. Management believes linerixibat has the potential to address a high unmet medical need for patients suffering from relentless itch and sleep disruption, conditions for which few effective treatments currently exist.
Outlook: Linerixibat is currently not approved anywhere in the world. It is under regulatory review in the US and UK. GSK is also investigating other treatments for liver diseases, including chronic hepatitis B, alcohol-related liver disease, and MASH.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2024 Annual Report on Form 20-F and Q1 2025 results. Approval is not guaranteed.
Investor Verification Checklist
- Verify the final approval decision timeline from the EMA and FDA following the MAA acceptance.
- Review the full GLISTEN Phase III trial data presented at the EASL Congress in May 2025 for detailed efficacy and safety statistics.
- Assess the potential market size and competitive landscape for cholestatic pruritus treatments in PBC.
- Monitor GSK's broader hepatology pipeline progress for chronic hepatitis B, ALD, and MASH.
- Check for any updates on the commercialization strategy and potential launch dates if approval is granted.